Tumors with positive PD-L1 expression were significantly associated with advanced stages of chordoma and the median PD-L1 expression score for the metastatic group was significantly higher than that for the primary group, suggesting that PD 1/L1-based immunotherapy may have potential in the treatment of chordoma, especially in advanced patients (10, 12). The gene discussed is CD274; the disease is chordoma.